Blinatumomab and CD19-directed CAR-T cells may be considered for relapsed MPAL expressing CD19, based on extrapolated data from BCP-ALL. Note: treatment line modifications may be necessary. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.